Lexaria signs CRO contracts for GLP-1 animal study #2
PUBT · 04/23 13:09
Share
Listen to the news
- Lexaria signed contracts with a contract research organization to run its 2026 Animal Study #2 (GLP-1-A26-2) on next-generation GLP-1 drug formulations.
- Study will test amycretin and retatrutide for compatibility with DehydraTECH, focusing on pharmacokinetics and tolerability.
- Dosing expected to begin within 30 days.
- Program will be funded from existing corporate resources.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved